View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
April 6, 2021updated 16 Apr 2021 6:44am

Anixa and OntoChem to enter next stage of Covid-19 therapy development

Anixa Biosciences and OntoChem are set to enter the next stage of developing their potential anti-viral therapy for Covid-19 on obtaining results from a Proof of Concept (POC) animal study.

Anixa Biosciences and OntoChem are set to enter the next stage of developing their potential anti-viral therapy for Covid-19 on obtaining results from a Proof of Concept (POC) animal study.

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

The companies are focused on developing an orally administrable, room-temperature stable, anti-viral therapy against SARS-CoV-2.

Anixa Biosciences president and CEO Dr Amit Kumar said: “Based on the promising preliminary data in the animal study, we have made the decision to proceed to the next stage of drug development.

“We have chosen one compound around which we will perform combinatorial synthetic medicinal chemistry to evaluate whether we can increase potency and optimise pharmacokinetics.

“The most promising compounds will again be evaluated in both in vitro and in vivo studies.”

According to data from the POC study in a Syrian Hamster model of Covid-19, which assessed two potential compounds and remdesivir, noticeable adverse effects were not observed on administering the drugs to infected hamsters.

On evaluating weight and behaviour, both Anixa compounds and remdesivir demonstrated comparable efficacy.

Furthermore, for all drugs tested, viral shedding data and autopsied lung inflammation analysis were inconclusive, probably because of the inadequacy of the animal model for such data.

OntoChem CEO Dr Lutz Weber said: “We expect this next phase of development to take roughly four to five months with another decision point at that time.

“We are pleased that our progress to date has been successful and we are looking forward to the next phase of development.”

In February, Anixa Biosciences initiated animal testing of two proprietary compounds for treating Covid-19.

One of the compounds tested in the animal study targeted an enzyme called endoribonuclease, while the other compound targeted another enzyme, which is the main protease Mpro.

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology